Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memantine for visual recovery after scleral buckling in macula-off rhegmatogenous retinal detachment
ACTRN12609000111279Phase 3Active, not recruiting
- Sponsor
- Tehran University of Medical Sciences
- Start
- Feb 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of memantine in rhegmatogenous retinal detachment (RRD) (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoint: Change in visual acuity. Started Feb 2008; status: active, not recruiting.
02
Drugs
memantine
03
Conditions
rhegmatogenous retinal detachment (RRD)
Beyond the preview
Go deeper on ACTRN12609000111279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000111279.